The kidney has been treated, for decades, like an organ you manage on the way to dialysis. Walden disagrees.
Walk past the glass on a Cambridge side street and you will not see anything cinematic. A few benches. People in lab coats. A whiteboard covered in the alphabet soup of nephrology - suPAR, FSGS, IgAN, podocyte. This is Walden Biosciences, a clinical-stage biotech of roughly two dozen people, and the thing it is trying to do is unfashionably specific: build medicines that go after kidney disease at its biological root.
That sounds modest until you remember how kidney disease is usually handled. The standard playbook slows the decline. It buys time. Eventually, for too many people, the road still ends at a dialysis machine or a transplant list. Walden's whole reason for existing is the suspicion that the road does not have to end there - that the kidney's filtration cells can be protected, and maybe restored, if you target them directly.
“Current therapies on the market only delay progression to dialysis or transplant, and do not directly target the kidneys.”
- Walden Biosciences, MassBio member spotlightInside each kidney sits a filter of staggering delicacy, and the stars of that filter are cells called podocytes. They wrap the tiny blood vessels of the kidney and decide what stays in your blood and what leaves in your urine. When podocytes get sick, protein leaks out (proteinuria), the filter frays, and chronic kidney disease grinds forward. Over 10% of the world's population lives with some form of it.
Here is the awkward part. Most of the drugs prescribed for kidney disease were not really designed for the kidney. They manage blood pressure, blood sugar, inflammation - upstream knobs that, turned far enough, ease the strain. Useful. Just not aimed at the actual machinery breaking down. For an organ this important, that is a curious oversight, the kind a field eventually has to answer for.
“Improving the function of podocytes represents the next frontier of renal medicine.”
- Walden BiosciencesWalden's founding science came from people who had spent careers staring at podocytes. Chief among them, scientific co-founder Jochen Reiser, whose lab traced a circulating blood protein - soluble urokinase plasminogen activator receptor, mercifully shortened to suPAR - and connected it to kidney damage. suPAR turned out to be one of the earliest known blood markers for both chronic kidney disease and acute kidney injury. A signal. And where there is a signal, there might be a target.
In October 2020, Walden launched out of ARCH Venture Partners with $51 million and a deliberately unhedged thesis: do not pick one mechanism, build two. The company decided to come at the kidney's filter from two directions at once - an antibody and a small molecule, each pointed at a different piece of the same broken machine.
A renal scientist whose work since the early 2000s linked suPAR to focal segmental glomerulosclerosis (FSGS) and, later, to its role as an early biomarker for CKD and acute kidney injury. The discoveries that became Walden's drug targets started on his bench.
Running the company is CEO and President Blaine McKee, Ph.D., who has spent more than two decades on complex diseases, alongside CFO Curt Dewan and Chief Medical Officer Andrew Blair, M.D. The bet they collectively placed: that decades of academic kidney biology could be translated into first-in-class drugs - the kind that have never existed before, which is exactly why they are hard.
“We are building on the decades-long, breakthrough work of our scientific founders to restore kidney function.”
- Walden Biosciences mission framingTwo programs. Each one a different way of telling the kidney's filter to hold the line.
A first-in-class, humanized monoclonal antibody that binds suPAR and blocks its pro-inflammatory attack on podocytes - the chain of events behind podocyte dysfunction, proteinuria and disease progression. Now in a Phase 2 basket study spanning common and rare glomerular diseases including FSGS, treatment-resistant minimal change disease, IgA nephropathy and primary membranous nephropathy.
A first-in-class small molecule built to stabilize and restore dynamin, an enzyme that keeps the structure of the kidney's filtration apparatus intact and protects podocytes from collapse. IND-enabling studies were completed in 2024, clearing the runway toward a Phase 1 start.
A "basket study" tests one drug across several different diseases at once - a bet that one mechanism (suPAR) sits underneath many kidney conditions that look unrelated on paper.
Conviction in biotech is measured in syndicates. Walden's cap table reads like a list of investors who do not write checks lightly: ARCH Venture Partners and UCB Ventures at launch; ATEM Capital and Mass General Brigham Ventures by the Series B. Two rounds, one direction of travel.
Money is not data, though - and Walden knows the difference. The proof that matters arrived in April 2024, when the lead antibody cleared its first human study: well tolerated, and crucially, it knocked suPAR down fast. In a field where so much never makes it out of the petri dish, watching the target move in actual people is the moment a thesis stops being a slide deck.
“WAL0921 was well-tolerated and demonstrated proof-of-biology through a rapid reduction in suPAR.”
- Walden Biosciences, 2024 Phase 1+ readoutThere is partnership work too. Walden has teamed with Primula to support a kidney-disease study, and its tie to Mass General Brigham Ventures plugs it into one of the country's deepest clinical research networks - useful when your trials need patients with rare, hard-to-find diseases.
Strip away the jargon and Walden's mission is a single verb swap. The status quo manages kidney disease. Walden wants to modify it - prevent the damage, slow the progression, and where possible restore the function that has been lost. "Disease-modifying" is a loaded phrase in medicine, the kind you are supposed to earn in a trial, not a press release. Walden has been careful to keep saying it anyway, which is either nerve or conviction, and in biotech the two are hard to tell apart.
What makes the company genuinely distinctive is not a single molecule but the angle of attack: target the kidney cells themselves - podocytes and the proximal tubular cells - rather than the upstream systems that happen to affect them. It is a narrower, harder, more honest way to chase the disease.
“Breakthrough, disease-modifying medicines that treat kidney disease by directly targeting the kidney.”
- Walden Biosciences missionThe interim Phase 2 data from the rare-disease cohorts is the next real test - the moment the suPAR thesis gets graded by patients who have run out of other options. If WAL0921 holds up there, and if WAL0623 reaches the clinic behind it, Walden stops being a promising idea about kidney biology and becomes something rarer: a company that changed what a kidney diagnosis means.
Return to that quiet Cambridge lab. The benches, the coats, the whiteboard alphabet soup. Nothing cinematic - just a small team trying to make the dialysis chair a little less inevitable for one in ten people on the planet. Most kidney drugs slow the road. Walden is still betting it can move the destination.
The kidney spent decades as the organ medicine learned to manage. Walden is treating it like one you can fix.
- The Walden bet, in one line